MBCProject_0984_T1_RNA
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.520
- G2M_CHECKPOINT+0.500
- MTORC1_SIGNALING+0.470
- INTERFERON_ALPHA_RESPONSE+0.410
- INTERFERON_GAMMA_RESPONSE+0.410
- UNFOLDED_PROTEIN_RESPONSE+0.380
- CHOLESTEROL_HOMEOSTASIS+0.370
- MYC_TARGETS_V1+0.340
- IL6_JAK_STAT3_SIGNALING+0.320
- ANDROGEN_RESPONSE+0.310
Top 10 suppressed
- ESTROGEN_RESPONSE_EARLY-0.460
- HEDGEHOG_SIGNALING-0.220
- KRAS_SIGNALING_DN-0.220
- ESTROGEN_RESPONSE_LATE-0.210
- WNT_BETA_CATENIN_SIGNALING-0.190
- PANCREAS_BETA_CELLS-0.180
- APICAL_JUNCTION-0.160
- UV_RESPONSE_DN-0.130
- APICAL_SURFACE-0.090
- HEME_METABOLISM-0.090
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_2EN3X6HB | high-grade glioma | — | 0.853 |
| 2 | AB5294B5-4A59-493A-9016-C2778735745F | — | — | 0.835 |
| 3 | FCD3124F-0F41-448E-B2B9-D9934D4EC1A7 | — | — | 0.832 |
| 4 | 54B7F258-FE9A-4EFE-87FB-465D587B1170 | — | — | 0.828 |
| 5 | f66a9fee-f63a-4398-b242-9c065bbe213d | — | — | 0.828 |
| 6 | A43D720D-0CA3-48CF-ADC7-5AC72BD5EEA9 | — | — | 0.817 |
| 7 | C3N-02087 | — | cohortA1 | 0.817 |
| 8 | 6f73b289-b329-40b4-9ac7-b4de6d775251 | — | — | 0.816 |
| 9 | BS_0WQJP6ZG | Supratentorial Ependymoma | — | 0.815 |
| 10 | SRR1313147 | — | E | 0.811 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 36 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.520 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.500 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.470 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.410 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.410 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.380 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.370 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.340 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.320 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.310 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.310 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.300 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.290 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.280 | Inavolisib | — uncovered |
| HYPOXIA | 0.270 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.230 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.220 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.210 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.200 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.200 | Inavolisib | — uncovered |